Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
RedHill Biopharma Completes Acquisition of Movantik from AstraZeneca
11:00am, Thursday, 02'nd Apr 2020
RedHill to promote Movantik® in the U.S. to expanded call points, including gastroenterologists, primary care physicians and additional specialists, along with Talicia® and.
Nektar Therapeutics (NKTR) Gets a Buy Rating from Mizuho Securities
09:09am, Thursday, 02'nd Apr 2020
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Nektar Therapeutics (NKTR), with a price target of $35.00. The
Nektar Therapeutics (NKTR) Gets a Buy Rating from Mizuho Securities
09:09am, Thursday, 02'nd Apr 2020
In a report released today,
Difei Yang
from Mizuho Securities maintained a
Buy
rating on Nektar Therapeutics (
NKTR
–
Research Report
), with a price target of
$35.00
. The company’s shares closed
Private Asset Management Inc Buys Uber Technologies Inc, Treehouse Foods Inc, New York ...
12:00am, Thursday, 02'nd Apr 2020Canaccord Genuity Keeps Their Buy Rating on Nektar Therapeutics (NKTR)
10:18am, Wednesday, 01'st Apr 2020
In a report released today, Arlinda Lee from Canaccord Genuity reiterated a Buy rating on Nektar Therapeutics (NKTR), with a price target of $25.00. The
Bank of New York Mellon Corp Has $39.53 Million Stock Holdings in Nektar Therapeutics (NASDAQ:NKTR)
08:54am, Wednesday, 01'st Apr 2020
Bank of New York Mellon Corp boosted its stake in Nektar Therapeutics (NASDAQ:NKTR) by 23.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commis
Revance Therapeutics (RVNC) Gets a Buy Rating from Mizuho Securities
08:13am, Wednesday, 01'st Apr 2020
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Revance Therapeutics (RVNC), with a price target of $35.00. The
Revance Therapeutics (RVNC) Gets a Buy Rating from Mizuho Securities
08:13am, Wednesday, 01'st Apr 2020
In a report released today,
Difei Yang
from Mizuho Securities maintained a
Buy
rating on Revance Therapeutics (
RVNC
–
Research Report
), with a price target of
$35.00
. The company’s shares close
Medicenna's Potential Best-In-Class IL-2 Superkine Program Making Progress
01:58am, Wednesday, 01'st Apr 2020
Medicenna's IL-2 Superkine, MDNA19, released recent data from non-human primate study suggesting best-in-class features. The small pilot study in monkeys showed
Sarepta Therapeutics (SRPT) Gets a Buy Rating from Mizuho Securities
08:07pm, Monday, 30'th Mar 2020
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Sarepta Therapeutics (SRPT), with a price target of $183.00. The
Sarepta Therapeutics (SRPT) Gets a Buy Rating from Mizuho Securities
08:07pm, Monday, 30'th Mar 2020
In a report released today,
Difei Yang
from Mizuho Securities maintained a
Buy
rating on Sarepta Therapeutics (
SRPT
–
Research Report
), with a price target of
$183.00
. The company’s shares clos
's Top Upgrades, Downgrades For March 30, 2020
01:35pm, Monday, 30'th Mar 2020
Upgrades
Cowen & Co. changed the rating for Cerner Corp (NASDAQ: CERN) from Market Perform to Outperform. Cerner earned $0.75 in the fourth quarter, compared...
Top Analyst Upgrades and Downgrades: Alphabet, Amazon, Amgen, Cerner, eBay, Gap, Nike, Nucor, P&G, TJX, ViacomCBS and More
01:05pm, Monday, 30'th Mar 2020
Monday's top analyst upgrades and downgrades included Alphabet, Amazon.com, Amgen, Cerner, eBay, Gap, Nike, Nucor, Procter & Gamble, TJX and ViacomCBS.
Raymond James likes Amgen in premarket analyst action
12:06pm, Monday, 30'th Mar 2020
BioSig Technologies (NASDAQ:BSGM) initiated with Buy rating and $9 (75% upside) price target at Roth Capital.Amgen (NASDAQ:AMGN) upgraded to Outperform with a $255 (29% upside) price target at Raymond
